Literature DB >> 993624

Clinical pharmacology of amikacin and kanamycin.

W M Kirby, J T Clarke, R D Libke, C Regamey.   

Abstract

During and after a 4-hr intravenous infusion of amikacin and kanamycin in a cross-over study in healthy adult male volunteers, average concentrations of drug in serum were similar, with half-lives of approximately 2 hr. Apparent volumes of distribution at the steady state averaged 30% of body weight, and the rate of renal clearance was less than the rate of creatinine clearance (83 vs. 120 ml/min), a finding that indicates tubular reabsorption. The rate of serum clearance was greater than the rate of renal clearance (100 vs 83 ml/min). Urinary excretion in 24 hr averaged 94% of the dose, and there was no binding of serum proteins. In another cross-over study, volunteers received single intramuscular injections of these antibiotics. Peak concentrations of drug in serum after 45 min to 2 hr averaged 19.9 and 19.0 mug/ml for amikacin and kanamycin, respectively. Serum half-lives between 4 and 8 hr after administration of drug were 2 hr, and an average of 94% of the dose was recovered in the urine in 24 hr. Thus, the pharmacologic properties of amikacin and kanamycin were virtually identical.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993624     DOI: 10.1093/infdis/135.supplement_2.s312

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development.

Authors:  Jian Wang; Shaun S Kumar; Catherine M Sherwin; Robert Ward; Gerri Baer; Gilbert J Burckart; Yaning Wang; Lynne P Yao
Journal:  Clin Pharmacol Ther       Date:  2019-02-10       Impact factor: 6.875

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

4.  Outbreak of multiply drug-resistant Proteus mirabilis originating in a surgical intensive care unit: in vitro susceptibility pattern.

Authors:  T T Yoshikawa; S A Shibata; A W Chow; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

5.  Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

6.  Determination of kanamycin concentration in serum by substrate-labeled fluorescent immunoassay.

Authors:  A F DeCastro; J D Place; C T Lam; C Patel
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.

Authors:  T P Kanyok; A D Killian; K A Rodvold; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Renal elimination of amikacin and the aging process.

Authors:  M Ducher; P Maire; C Cerutti; Y Bourhis; F Foltz; P Sorensen; R Jelliffe; J P Fauvel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Amikacin pharmacokinetics in pediatric patients with malignancy.

Authors:  T G Cleary; L K Pickering; W G Kramer; S Culbert; L S Frankel; S Kohl
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

10.  Amikacin assay in serum by high-performance liquid chromatography.

Authors:  S K Maitra; T T Yoshikawa; C M Steyn; L B Guze; M C Schotz
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.